Bio Impact Capital LLC Merus N.V. Transaction History

Bio Impact Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.64 - $28.93 $21,846 - $33,905	-1,172 Reduced 0.13%	918,310 $18.4 Million
Q1 2022 May 13, 2022	SELL	$23.58 - $30.91 $184,395 - $241,716	-7,820 Reduced 0.84%	919,482 $24.3 Million
Q4 2021 Feb 11, 2022	SELL	$20.0 - $32.29 $292,920 - $472,919	-14,646 Reduced 1.55%	927,302 $29.5 Million
Q3 2021 Nov 15, 2021	BUY	$16.48 - $27.23 $3.97 Million - $6.56 Million	241,069 Added 34.4%	941,948 $20.7 Million
Q2 2020 Aug 12, 2020	BUY	$10.5 - $17.36 $7.36 Million - $12.2 Million	700,879 New	700,879 $11.3 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.92B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.